Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
ROSCREA, Ireland, April 12, 2022 /PRNewswire/ -- Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, announced today that it has entered into a share subscription agreement with GEM Global Yield LLC SCS ("GEM"), a Luxembourg-based private equity group for an investment of up to...
BRV China-backed Global Leading Exoskeleton Company RoboCT Secures RMB100 million Series A+ Financing
BRV China impressed with surging growth in China's robotics sector, highlights RoboCT as a best-in-class example of a new wave of globally competitive Chinese robotic technology HONG KONG, April 12, 2022 /PRNewswire/ -- Hangzhou RoboCT Technology Development Co., Ltd., a global leading exoskeleton company, recently completed RMB100 million series A+ financing led by Fortune Capital and followed by Essence...
Esaote S.p.A. turns 40 and is confirmed as a leading player in the world market for diagnostic imaging with ultrasound systems, magnetic resonance imaging and information technology for healthcare
GENOA, Italy, April 12, 2022 /PRNewswire/ -- Esaote S.p.A., a leading biomedical company in the diagnostic imaging sector - in the fields of ultrasound, magnetic resonance and Information Technology for health - celebrates forty years of activity. Eugenio Biglieri, COO and Franco Fontana, CEO Esaote Group Born from scratch in...
New Clinical Advisory Board to support PromarkerD global rollout
Proteomics International establishes world class Clinical Advisory Board promarkerd.com/clinical-advisory-board Comprises highly-respected physicians specialising in diabetes and kidney disease care from the United States, Europe and Australia New advisory board offers doctors' viewpoint in commercialisation of the PromarkerD blood test for the prediction of diabetic kidney disease Doctors will ultimately order...
CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States
CHENGDU, China, April 12, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that its new drug candidate CMG901 (the "Claudin 18.2 antibody drug conjugates") for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma has been granted the Orphan-drug Designation by the Food and Drug Administration of the United States (the "FDA") recently. Previously, in March 2021, the Company received the...
Abbott Senior Medical Director joins Nutromics as inaugural Chief Medical Officer
MELBOURNE, Australia, April 12, 2022 /PRNewswire/ -- Australian and US MedTech start-up Nutromics (Nutromics or the Company), a global leader in DNA-based biosensors, today announced that Dr Agim Beshiri, most recently Senior Medical Director at Abbott Laboratories, has joined the organisation as its inaugural Chief Medical Officer (CMO). Dr Agim Beshiri Dr Beshiri is an accomplished senior medical...
VenusP-Valve(TM) obtains CE marking under MDR and debuts in Europe as China’s first valve product
HANGZHOU, China, April 12, 2022 /PRNewswire/ -- On April 8th, 2022, VenusP-ValveTM, Venus Medtech's in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, received CE marking under the Medical Devices Regulation (MDR) to be marketed in Europe. Designed to treat patients with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract (RVOT) stenosis, VenusP-ValveTM is...
Strong Growth in Digital Health Powers MediHeroes, A Cross Border B2B Medical Platform
SINGAPORE, April 12, 2022 /PRNewswire/ -- MediHeroes will launch a "Verify Before Buy" platform created especially for suppliers, buyers and service providers in the MedTech industry on April 15, 2022. A transformative industry platform, MediHeroes helps buyers and sellers save months to years of time, with credentials validations and go-to-market services. Strong Growth in Digital Health Powers...
ProstACT Update: TARGET Study Ethics Approval
MELBOURNE, Australia, April 12, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its ProstACT TARGET Phase II clinical trial of the Company's prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients experiencing a first recurrence of prostate-specific antigen (PSA) after initial therapy for prostate cancer, has been granted...
The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of Small Cell Lung Cancer Accepted by NMPA
SHANGHAI, April 11, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of HANSIZHUANG (serplulimab), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with chemotherapy for the first-line treatment of extensive stage small cell lung cancer (ES-SCLC) has been accepted by the National Medical Products Administration (NMPA). Henlius also...
